Pancreatic islet cells in microfluidic-spun hydrogel microfibers for the treatment of diabetes

Abstract

Islet transplantation has been developed as an effective cell therapy strategy to treat the progressive life-threatening disease Type 1 diabetes (T1DM). To mimic the natural islets and achieve immune isolation, hydrogel encapsulation of multiple islet cell types is the current endeavor. Here, we present a microfiber loading with pancreatic α and β cells by microfluidic spinning for diabetes treatment. Benefiting from microfluidic technology, the cells could be controllably and continuously loaded in the alginate and methacrylated hyaluronic acid (Alg-HAMA) microfiber and maintained their high bioactivity. The resultant microfiber could then hold the capacity of dual-mode glucose responsiveness attributed to the glucagon and insulin secreted by the encapsulated pancreatic α and β cells. After transplantation into the brown adipose tissue (BAT), these cell-laden microfibers showed successful blood glucose control in rodents and avoided the occurrence of hypoglycemia. These results conceived that the multicellular microfibers are expected to provide new insight into artificial islet preparation, diabetes treatment, and regenerative medicine as well as tissue engineering.

Statement of significance

• •
  The microfibers were generated with a double network of alginate and methacrylated hyaluronic acid.
• •
  The microfibers could simultaneously encapsulate pancreatic α and β cells and showed dual-mode glucose responsiveness.
• •
  The cell-laden microfibers maintained a long-term hormone-releasing function in vivo.
• •
  Cell-laden microfibers transplanted into diabetic mice could achieve glycemic control for 6 weeks.